



TO

All Providers, HMOs and Other Managed Care Programs

REGARDING

COVID-19 Monoclonal Antibody Infusions Rate Increase

COVID-19 Monoclonal Antibody Infusions Rate Increase

Effective for dates of service on and after May 6, 2021, ForwardHealth will increase reimbursement rates for COVID-19 monoclonal antibody infusions to \$450 for all currently allowable claim submissions. This change aligns with updated Medicare reimbursement.

Impacted procedure codes include:

- M0243 (Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring)
- M0245 (Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring)

For more information on pricing and reimbursement, providers should refer to the appropriate maximum allowable fee schedule on the [Max Fee Schedules](#) page of the ForwardHealth Portal.

COVID-19-related ForwardHealth Alerts and Updates are available on the [COVID-19: ForwardHealth News and Resources](#) page of the ForwardHealth Portal.